New study tests which fiber supplement causes least gas
NCT ID NCT07525180
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares three fiber supplements—LOAM prebiotic fiber, inulin, and a placebo—to see which causes the least intestinal gas and digestive discomfort. 125 healthy adults on low-fiber diets will take one supplement daily for four weeks. A wearable device measures gas, and participants track symptoms remotely.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LOAM prebiotic fiber, inulin, and cellulose placebo (dietary supplements)
- What this could lead to
- If LOAM causes less gas than inulin, it could become a more comfortable prebiotic option for people starting fiber supplements.
- What could go wrong
- This is a small, early-stage study in healthy people, not patients. Results may not apply to those with digestive conditions, and the wearable device is still being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 125 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Male or female adults aged 18 to 65 years 2. Body mass index 18.5 to 30 kg/m2 3. Habitual daily fiber intake of fewer than 10 grams per day, as self-reported at screening 4. No current use of fiber supplements, prebiotic supplements, or probiotic supplements 5. No use of fiber supplements, prebiotics, probiotics, or antibiotics within the past 4 months 6. Willing and able to consume one daily fiber supplement (mixed with water) for the duration of the study 7. Willing and able to wear the Ventos intestinal gas monitoring device for approximately 22 hours on designated monitoring days (Tuesdays and Saturdays) for the full 5-week study period 8. Willing and able to complete daily and weekly digital questionnaires and symptom diaries using the Alethios platform 9. Access to a smartphone or computer with internet access 10. Able to read and understand English 11. Non-user (never used, or former user defined as cessation 12 or more months) of tobacco or nicotine products with no plans to begin use during the study period 12. Willing to maintain habitual diet, physical activity, and body weight throughout the trial 13. Willing to refrain from exclusionary medications, supplements, and products throughout the study 14. Willing to provide informed consent electronically 15. Not currently enrolled in any other clinical trial, supplement study, or consumer health research study Exclusion Criteria 1. Diagnosis of any gastrointestinal condition, including but not limited to IBS, IBD (Crohn's Disease or Ulcerative Colitis), celiac disease, diverticulitis, gastroparesis, clinically significant lactose or gluten intolerance or other food or ingredient allergies, or any chronic or acute GI condition requiring medical management (e.g., GERD) 2. Perception that they have more than 40 flatus per day 3. Currently undergoing chemotherapy or any other treatment that affects the digestive system 4. Known allergy or sensitivity to any ingredient in the study supplement 5. Unwilling to discontinue any current fiber supplement use at least 14 days prior to study initiation 6. Habitual dietary fiber intake of 10 or more grams per day 7. Consumption of supplemental inulin/chicory root or inulin/chicory root-fortified foods and beverages equivalent to more than 10 g inulin per day within 1 month of screening 8. Participation in another research study within 30 days prior to screening that could confound study outcomes 9. Recent history (within 12 months of screening) of alcohol or substance abuse 10. Habitual use (daily) of marijuana and hemp products including CBD products within 30 days of screening 11. Currently or planning to be on a weight loss regimen during the study 12. Use of weight loss medications, incretin mimetics, and/or GLP-1 agonists in the 3 months prior to screening 13. Chronic use (daily on a regular basis) of anti-inflammatory medications (e.g., NSAIDs) within 1 month of screening 14. Expected to receive a COVID-19 vaccine during the study period 15. Antibiotic use within 3 months of screening and throughout the study period 16. Any medical condition that would make participation unsafe or interfere with data quality 17. Currently pregnant or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy participants are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Alethios
San Francisco, California, 94109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly
- New drug RO7830698 put to the test for COPD
- Three pill versions of one drug go head to head in the bloodstream
- Pfizer tests RSV vaccine aimed at older adults
- Radioactive tracer maps where a new drug goes in the body
- Radioactive tag lets scientists follow an experimental drug through the human body